A DNA PLASMID MELANOMA CANCER VACCINE, SCIB1, COMBINED WITH NIVOLUMAB + IPILIMUMAB IN PATIENTS WITH ADVANCED UNRESECTABLE MELANOMA: EFFICACY AND SAFETY RESULTS FROM THE OPEN-LABEL PHASE 2 SCOPE TRIAL

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2023
This article has no abstract
Epistemonikos ID: 47f973e0a8a70656688e83db024e297f6ecc4bc8
First added on: Feb 17, 2025